ACM
ELEV
Aisling Capital Management’s Elevation Oncology ELEV Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.04M | Hold |
2,834,910
| – | – | 0.29% | 9 |
|
|
2025
Q1 | $735K | Hold |
2,834,910
| – | – | 0.25% | 10 |
|
|
2024
Q4 | $1.59M | Hold |
2,834,910
| – | – | 0.56% | 11 |
|
|
2024
Q3 | $1.7M | Hold |
2,834,910
| – | – | 0.65% | 12 |
|
|
2024
Q2 | $7.65M | Hold |
2,834,910
| – | – | 3.31% | 4 |
|
|
2024
Q1 | $14.5M | Hold |
2,834,910
| – | – | 4.92% | 4 |
|
|
2023
Q4 | $1.52M | Hold |
2,834,910
| – | – | 0.45% | 11 |
|
|
2023
Q3 | $1.88M | Hold |
2,834,910
| – | – | 0.77% | 12 |
|
|
2023
Q2 | $4.31M | Hold |
2,834,910
| – | – | 2.11% | 9 |
|
|
2023
Q1 | $5.39M | Hold |
2,834,910
| – | – | 2.59% | 6 |
|
|
2022
Q4 | $2.69M | Hold |
2,834,910
| – | – | 1.78% | 9 |
|
|
2022
Q3 | $3.2M | Hold |
2,834,910
| – | – | 2.13% | 9 |
|
|
2022
Q2 | $3.97M | Hold |
2,834,910
| – | – | 2.83% | 8 |
|
|
2022
Q1 | $7.14M | Hold |
2,834,910
| – | – | 3.86% | 7 |
|
|
2021
Q4 | $17.1M | Hold |
2,834,910
| – | – | 6.02% | 5 |
|
|
2021
Q3 | $22.1M | Hold |
2,834,910
| – | – | 4.4% | 5 |
|
|
2021
Q2 | $38.5M | Buy |
+2,834,910
| New | +$38.5M | 6.16% | 2 |
|